DifGen Pharmaceuticals Receives FDA Clearance to Begin Clinical Development for a Single Injection treatment for Advanced Breast Cancer DFGN-101
MIRAMAR, Fla., July 27, 2026 /PRNewswire/ -- Agency issues "study may proceed" letter; development pathway does not require a clinical endpoint efficacy study. DifGen Pharmaceuticals LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's...
MIRAMAR, Fla., July 27, 2026 /PRNewswire/ -- Agency issues "study may proceed" letter; development pathway does not require a clinical endpoint efficacy study. DifGen Pharmaceuticals LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.